Michael W. Dunne
2019
In 2019, Michael W. Dunne earned a total compensation of $883.1K as Chief Scientific Officer at Iterum Therapeutics plc, a 23% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $81,000 |
|---|---|
| Option Awards | $317,900 |
| Salary | $402,794 |
| Stock Awards | $73,890 |
| Other | $7,524 |
| Total | $883,108 |
Dunne received $402.8K in salary, accounting for 46% of the total pay in 2019.
Dunne also received $81K in non-equity incentive plan, $317.9K in option awards, $73.9K in stock awards and $7.5K in other compensation.
Rankings
In 2019, Michael W. Dunne's compensation ranked 9,830th out of 13,971 executives tracked by ExecPay. In other words, Dunne earned more than 29.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,830 out of 13,971 | 30th |
Division Manufacturing | 3,969 out of 5,701 | 30th |
Major group Chemicals And Allied Products | 1,513 out of 2,200 | 31st |
Industry group Drugs | 1,294 out of 1,886 | 31st |
Industry Pharmaceutical Preparations | 961 out of 1,398 | 31st |
Source: SEC filing on May 7, 2020.
Dunne's colleagues
We found two more compensation records of executives who worked with Michael W. Dunne at Iterum Therapeutics plc in 2019.